One of the major applications of CBLI’s apoptosis-modulating technology is for cancer treatment. Most human tumors acquire defects that make them resistant to apoptosis such as constitutive activation of the anti-apoptotic factor NF-kappaB

Despite the significant threat of high dose radiation exposure that exists in our world today, there are currently no highly effective and non-toxic anti-radiation treatments available. CBLI is building upon its understanding of the molecular mechanisms